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Abstract
Background: Metastasis remains the major cause of death in nasopharyngeal carcinoma (NPC). Yippee-like 3
(YPEL3) plays an important role in tumorigenesis. However, its function and mechanism in NPC has not been
systematically explored.
Methods: We evaluated YPEL3 expression in NPC cell lines and tissues using real-time PCR and western blotting.
Then, we established NPC cell lines that stably overexpressed YPEL3 and knocked down YPEL3 expression to explore its
function in NPC in vitro and in vivo. Additionally, we investigated the potential mechanism of YPEL3 action by identifying
the Wnt/β-catenin signaling pathway downstream genes using western blotting.
Results: YPEL3 was downregulated in NPC cell lines and tissue samples. Ectopic expression of YPEL3 inhibited NPC cell
migration and invasion in vitro; while silencing of YPEL3 promoted NPC cell migration and invasion. Further study
indicated that overexpression of YPEL3 inhibited NPC cell epithelial–mesenchymal transition (EMT) and that
silencing it enhanced EMT. Overexpression of YPEL3 suppressed NPC cell lung metastasis in vivo. The mechanism
study determined that YPEL3 suppressed the expression levels of Wnt/β-catenin signaling pathway downstream
genes and the nuclear translocation of β-catenin.
Conclusions: YPEL3 suppresses NPC EMT and metastasis by suppressing the Wnt/β-catenin signaling pathway,
which would help better understanding the molecular mechanisms of NPC metastasis and provide novel therapeutic
targets for NPC treatment.
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Background
Nasopharyngeal carcinoma (NPC) is a head and neck
cancer with a high prevalence rate (20–50 cases per
100,000 people) in South China [1, 2]. Although intensity-
modulated radiotherapy and chemotherapy have improved
the local control, distant metastasis remains the major
cause of death in NPC [3, 4]. Thus, better understanding
the mechanisms underlying NPC metastasis is essential for
developing novel treatment strategies.
Yippee-like 3 (YPEL3), a protein encoded by the
Drosophila Yippee gene [5], is a member of the putative
zinc finger motif, which contains proteins with a high
degree of conservation among the cysteines and histi-
dines [6]. Investigators first identified YPEL3 as SUAP,
or small unstable apoptotic protein, which induced IL3
removal in a myeloid precursor cell line [7]. A number
of studies have demonstrated that YPEL3 suppresses
tumor growth, proliferation and metastasis in several
types of cancer, such as in breast tumors [8] and colon tu-
mors [9]. Recent studies have found that murine YPEL3 is
related to cell growth inhibition through apoptosis, which
is involved in the programmed cell death of murine mye-
loid precursor cells during differentiation [7, 10]. However,
the roles and mechanism of YPEL3 in NPC development
and progression remain unclear.
Recent studies indicate that the Wnt/β-catenin signal-
ing pathway is overactivated in several human cancers,
including NPC [11–13]. Briefly, Wnt ligand binding ini-
tiates the Wnt/β-catenin pathway, and the cytoplasmic
degradation complex is inhibited, which leads to T-cell
factor/lymphoid enhancer factor activation of the Wnt
downstream genes. The Wnt/β-catenin signaling path-
way is one of the most important signaling pathways
identified as being involved in tumor metastasis [14–17];
however, whether the molecular mechanism of YPEL3 is
associated with the pathway and the relevance between
YPEL3 and Wnt/β-catenin signaling in NPC remain to
be elucidated.
In this study, we investigated the roles and mechanism
of YPEL3 in NPC metastasis. We discovered that YPEL3
expression was decreased in NPC cell lines and clinical
samples. YPEL3 overexpression inhibited NPC cell inva-
sion and metastasis in vitro and in vivo. Further studies
demonstrated that YPEL3 overexpression inhibited epi-
thelial–mesenchymal transition (EMT) by suppressing
the nuclear translocation of β-catenin.
Methods
Cell culture and clinical specimens
Human NPC cell lines (CNE-1, CNE-2, SUNE-1, HNE-
1, HONE-1, 5-8 F, 6-10B) were cultured in RPMI 1640
medium (Invitrogen, Carlsbad, CA, USA) supplemented
with 10 % (v/v) fetal bovine serum (FBS; Gibco, Grand
Island, NY, USA). The human immortalized nasopharyngeal
epithelial NP69 cell line was grown in keratinocyte
serum–free medium (Invitrogen, Carlsbad, CA, USA) sup-
plemented with bovine pituitary extract (BD Biosciences,
San Jose, CA, USA). We maintained 293FT cells in
Dulbecco’s modified Eagle’s medium (Invitrogen, Carls-
bad, CA, USA) supplemented with 10 % FBS. In addition,
22 freshly frozen NPC biopsy samples and 12 normal
nasopharyngeal epithelium samples were collected from
Sun Yat-sen University Cancer Center. This study was ap-
proved by the Institutional Ethical Review Boards of our
center, and written informed consent was obtained from
each patient.
RNA isolation and reverse transcription–PCR (RT-PCR)
Total RNA was extracted using TRIzol (Invitrogen,
Carlsbad, CA, USA) and quantified at 260 nm by a
NanoDrop 2000 spectrophotometer (Thermo Scientific,
Waltham, MA, USA). Total RNA (2 μg) was reverse-
transcribed to complementary DNA (cDNA) using an
RT kit (Promega, Madison, WI, USA). Quantitative PCR
was performed in triplicate using Platinum SYBR Green
qPCR Super Mix-UDG reagents (Invitrogen, Carlsbad,
CA, USA) on a CFX96 Touch™ sequence detection system
(Bio-Rad, Hercules, CA, USA). The following primer
sequences were used for amplification: YPEL3 forward, 5′-
CCACGACGACCTCATCTC-3′; reverse, 5′-CATATTTC
CAGCCCAAAGT-3′; E-cadherin forward, 5′-GAAGAG
GACCAGG ACTTTGAC-3′; reverse, 5′- GTAGTCATA
GTCCTGGTCTTTGTC-3′; Vimentin forward, 5′- TCAG
ACAGGATGTTGACAATGC-3′; reverse, 5′- TCATATT
GCTGACGTACGTCAC-3′. GAPDH was used as the
endogenous control, and the comparative threshold cycle
(2-ΔΔCT) equation was used to calculate the relative
expression levels.
Western blotting
Cultured cells were washed twice with ice-cold phosphate-
buffered saline (PBS), solubilized in a lysis buffer contain-
ing 1 mmol/L protease inhibitor cocktail (FDbio Science,
Hangzhou, China) on ice, and quantified using the bicinch-
oninic acid method. Cell lysate protein samples were
separated by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and then electrophoretically transferred to
polyvinylidene difluoride membranes (Millipore, Billerica,
MA, USA). The membranes were blocked with 5 %
skim milk in Tris-buffered saline–Tween (TBST) buffer
(10 mmol/L Tris–HCl [pH 7.4], 150 mmol/L NaCl,
0.1 % Tween 20) for 2 h. Protein expression was
detected following overnight incubation at 4 °C using
primary antibodies against HA (1:2000, Sigma-Aldrich,
USA); YPEL3 (1:100, Abcam, Cambridge, MA, USA), β-
catenin (1:500, Proteintech, Wuhan, China), c-MYC
(1:2000, Proteintech, Wuhan, China), cyclin D1 (1:500,
Proteintech, Wuhan, China), α-catenin (1:500, BD
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Biosciences, San Jose, CA, USA), E-cadherin (1:500, BD
Biosciences, San Jose, CA, USA), vimentin (1:500, BD
Biosciences, San Jose, CA, USA), GSK3β(1:1000, Proteintech,
Wuhan, China), TBP (1:800, Proteintech, Wuhan, China),
and GAPDH (1:500, Proteintech, Wuhan, China). Thereafter,
the membranes were washed and incubated for 1 h at
room temperature with the appropriate horseradish per-
oxidase–conjugated secondary antibody. After the mem-
branes were washed with TBST buffer three times, the
proteins were visualized with an enhanced chemilumines-
cence reagent (Beyotime, Shanghai, China). The bands
were analyzed using Image J software.
Stable cell line establishment and YPEL3 small interfering
RNAs (siRNAs)
The pSin-EF2-puro-YPEL3-HA or pSin-EF2-puro-vector
plasmids were obtained from Land. Hua Gene Biosci-
ences (Guangzhou, China). All plasmids were verified by
DNA sequencing before use; the pSin-EF2-puro-vector
plasmid was used as the control. Stably transfected cells
were selected using puromycin and were confirmed using
quantitative RT-PCR. SiRNA#1 targeting YPEL3-Homo-
974 (siYPEL3), which was obtained from GenePharma
Co., Ltd (Shanghai, China), was a pool of siRNAs for the
YPEL3 gene (sense strand: 5′-GCCACCUCUUCAACU
CAGTT-3′; antisense strand: 5′-CUGAGUUGAAGAG
GUAGGCTT-3′); siRNA#2 targeted YPEL3-Homo-838
cDNA (sense strand: 5′-GCGGAU UUCAAAGCCCAAG
TT-3′; antisense strand: 5′-CUUGGGUUUGAAUCCGC
TT-3′).
Wound healing assay
CNE-2 and SUNE-1 cells were seeded onto a 6-well cul-
ture plate and cultured to a subconfluent state in complete
medium. After 24-h starvation in serum-free medium, cell
monolayers were linearly scraped with a P-200 pipette tip.
Cells that had detached from the bottom of the wells were
gently aspirated and incubated in serum-free medium for
24 h. The width of the scratch was monitored under a
microscope and quantified in terms of the difference
between the original width of the wound and the width
after cell migration.
Transwell migration and invasion assays
Transwell migration and invasion assays were carried out
using Transwell chambers (Corning, Tewksbury, MA,
USA) with 8-μm pore polyethylene membranes. For the
migration assay, cells were placed in the upper chamber of
each insert that had not been coated with Matrigel (BD
Biosciences, San Jose, CA, USA). For the invasion assay,
cells were placed in the upper chamber of inserts that
had been pre-coated with Matrigel. Plasmid- or siRNA-
transfected CNE-2 and SUNE-1 cells (5 × 104 for the
migration assay;1 × 105 for the invasion assay) were
added to the upper chamber in serum-free medium,
and the lower chamber contained culture medium with
20 % FBS to act as a chemoattractant. The cells were
incubated for 12 h or 24 h at 37 °C in 5 % CO2, and
then they were fixed and stained. Cells on the under-
sides of the filters were observed and counted under ×
200 magnification.
Immunofluorescence staining
CNE-2 and SUNE-1 cells were cultured on coverslips in
6-well plates, washed with PBS, fixed with 4 % parafor-
maldehyde for 30 min, and permeabilized with 0.5 %
Triton X-100 for 10 min. After blocking with 1 % bovine
serum albumin for 1 h, the cells were immunostained
with antibody against E-cadherin or vimentin at a 1:500
dilution. The cells were washed with PBS and incubated
with Alexa Fluor–conjugated goat anti-mouse secondary
antibody (1:200, A11011; Invitrogen). After washing with
PBS, the nuclei were stained with DAPI (Invitrogen,) for
15 min, and fluorescence images were obtained using a
confocal scanning microscope (OLYMPUS FV1000;
Olympus, Tokyo, Japan) and analyzed using Image-Pro
Plus 6.0 software.
Animal experiments
Female, pathogen-free, athymic nude mice were purchased
from Charles River Laboratories (Beijing, China) (n = 9mice
per group). SUNE-1 cells (1 × 106) stably overexpressing
vector or YPEL3 that had been resuspended in 200 μL
serum-free medium were injected intravenously into the
tail veins of the mice. After 8 weeks, the mice were sacri-
ficed and the lung tissues were fixed for calculating the
numbers of macrometastatic nodes formed on the surface
of lungs. Then, the tissues were paraffin-embedded, serial
5-μm tissue sections were cut, and one of every ten sections
was stained with hematoxylin–eosin (HE) for examination
of micrometastatic nodes formed in the lungs as previously
described [18, 19]. All animal research was conducted in
accordance with the detailed rules approved by the Animal
Care and Use Ethnic Committee of Sun Yat-sen University
Cancer Center and all efforts were made to minimize ani-
mal suffering.
Statistical analysis
All statistical analyses were carried out with SPSS software
(standard version 17.0, Chicago, IL, USA). All experiments
were performed in three independent experiments and all
data are presented as the mean ± SD. Significant differ-
ences between two groups were analyzed using two-tailed
unpaired Student’s t-test and a P-value <0.05 was consid-
ered statistically significant.
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Results
YPEL3 is downregulated in NPC cells and tissues
The mRNA and protein expression levels of YPEL3 in
the normal nasopharyngeal epithelial NP69 cell line and
seven NPC cell lines were assessed by quantitative RT-
PCR and western blotting. Compared to NP69 cells,
YPEL3 was significantly downregulated in the NPC cell
lines at both mRNA and protein level (Fig. 1a, b). We
also investigated the YPEL3 mRNA levels in 12 frozen
NPC tissues and 12 normal nasopharyngeal epithelial
tissues, and observed that YPEL3 mRNA was expressed
at considerably lower levels in the NPC tissues (Fig. 1c).
Western blotting validated the decreased YPEL3 protein
levels in the NPC tissues (Fig. 1d). These results indicate
that decreased YPEL3 expression may promote NPC de-
velopment and progression.
YPEL3 suppressed NPC cell migration and invasion in
vitro
To study whether YPEL3 affects the migratory and inva-
sive abilities of NPC cells, we performed wound healing,
Transwell migration, and invasion assays using CNE-2
and SUNE-1 cells stably overexpressing YPEL3 or vec-
tor. As shown in Fig. 2a, Western blotting validated that
YPEL3 protein level was obviously elevated after stably
overexpressing YPEL3 in NPC cells. The wound healing
assay demonstrated that the migratory ability of CNE-2
and SUNE-1 cells stably overexpressing YPEL3 was
much lower than that of cells expressing vector plasmid
(Fig. 2b). Overexpressing YPEL3 suppressed the migra-
tory (Fig. 2c) and invasive (Fig. 2d) abilities of the NPC
cells as determined by the Transwell migration and
invasion assays. These findings indicate that YPEL3 in-
hibits the migratory and invasive abilities of NPC cells in
vitro.
Silencing YPEL3 promoted NPC cell migration and
invasion in vitro
To further investigate whether silencing of YPEL3 affects
the migratory and invasive abilities of NPC cells, we
transiently transfected CNE-2 and SUNE-1 cells with
siYPEL3 or control siRNA, and performed wound heal-
ing, Transwell migration, and invasion assays. As shown
in Fig. 3a, Western blotting confirmed that the YPEL3
protein level was remarkably decreased after silencing of
YPEL3 in NPC cells. The wound healing and Transwell
migration assays showed that cells transfected with siY-
PEL3 migrated more slowly than cells transfected with
control siRNA (Fig. 3b, c). Knocking down YPEL3 pro-
moted NPC cell invasive capability as determined by the
Transwell invasion assay (Fig. 3d). These findings indi-
cate that silencing YPEL3 promotes the migratory and
invasive abilities of NPC cells in vitro.
YPEL3 suppressed NPC cell EMT
As EMT is important for the acquisition of metastatic po-
tential in tumors, we determined the expression levels of
the epithelial markers E-cadherin and α-catenin, and that
of the mesenchymal marker vimentin using immunofluor-
escence staining and western blotting. Immunofluorescence
staining revealed that YPEL3 overexpression significantly
rescued E-cadherin expression but inhibited vimentin ex-
pression (Fig. 4a); western blotting revealed similar changes
in epithelial and mesenchymal marker expression in the
Fig. 1 YPEL3 mRNA and protein expression levels in NPC cell lines and tissues. a-b Quantitative RT-PCR (a) and western blotting analysis (b) of
YPEL3 expression levels in NPC cell lines. c Quantitative RT-PCR analysis of YPEL3 mRNA expression levels in NPC (n = 12) and normal nasopharyngeal
epithelial tissues (n = 12); d western blotting analysis of YPEL3 protein levels in NPC (T, n = 4) and normal nasopharyngeal epithelial tissues (N, n = 4).
All of the experiments were performed at least three times. Data presented are the mean ± SD; the P-value was calculated using the Student t-test
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CNE-2 and SUNE-1 cells overexpressing of YPEL3 (Fig. 4b).
Conversely, silencing YPEL3 suppressed E-cadherin and
α-catenin expression but increased vimentin expression
(Fig. 4c). In addition, Spearman’s correlation analysis
showed thatYPEL3 mRNA expression was positively
correlated with E-cadherin expression, and inversely
correlated with vimentin expression in 10 NPC tissue sam-
ples (r = 0.803 and r = -0.754, respectively; both p < 0.001,
Fig. 4d). These observations demonstrate that YPEL3
suppresses NPC cell EMT.
YPEL3 suppressed lung metastasis in vivo
To determine the role of YPEL3 in NPC cell metastasis
in vivo, we constructed a lung metastasis model by
injecting SUNE-1 cells stably overexpressing YPEL3 or
vector into the tail veins of nude mice. After 8 weeks,
fewer macroscopic metastatic nodes were seen on the
lung surfaces of the YPEL3-overexpressing group as
compared with the vector group (Fig. 5a, b). In addition,
there were smaller and fewer microscopic metastatic
nodules in the YPEL3-overexpressing group than in the
vector group (Fig. 5c, d). These results indicate that
YPEL3 suppresses NPC cell metastasis, suggesting YPEL3
functions as a negative regulator of metastasis.
YPEL3 inhibits NPC metastasis through the Wnt/β-catenin
signaling pathway
As Wnt/β-catenin plays a critical in EMT induction and
maintenance, we examined the protein expression of the
Wnt/β-catenin signaling genes for GSK3β, β-catenin,
Fig. 2 Effects of YPEL3 overexpression on NPC cell migration and invasion in vitro. a Representative western blotting analysis of YPEL3 overexpression
in CNE-2 and SUNE-1 cells. GAPDH served as the loading control. b-d Representative images and quantification of the effects of YPEL3 overexpression
on the migratory and invasive abilities of CNE-2 and SUNE-1 cells as determined by wound healing (b), Transwell migration (c), and invasion (d) assays.
All of the experiments were performed at least three times. Data presented are the mean ± SD; **P < 0.01 compared with control using Student t-test
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c-MYC, and cyclin D1 in CNE-2 and SUNE-1 cells over-
expressing YPEL3 or in which YPEL3 had been silenced to
explore the YPEL3 mechanism underlying NPC metasta-
sis. Overexpressing YPEL3 elevated the protein expression
of GSK3β and suppressed the protein expression of β-
catenin, c-MYC, and cyclin D1(Fig. 6a). Conversely, silen-
cing YPEL3 inhibited the protein expression of GSK3β
and increased the protein expression of β-catenin, c-MYC,
and cyclin D1 the genes (Fig. 6b). Moreover, subcellular
protein fraction study confirmed that YPEL3 overexpres-
sion decreased nuclear β-catenin expression and increased
cytoplasmic β-catenin expression (Fig. 6c), which indicates
that the suppressive effect of YPEL3 may take place
through the inhibition of β-catenin nuclear translocation.
These data demonstrate that YPEL3 plays a critical role in
mediating the Wnt/β-catenin signaling pathway.
Discussion
In this study, we show for the first time that YPEL3 ex-
pression is downregulated in NPC cell lines and tissue
samples at both mRNA and protein level. Restoring
YPEL3 expression suppressed NPC cell migration and
invasion in vitro and in vivo and reversed EMT by inhi-
biting the Wnt/β-catenin signaling pathway. In light of
these findings, we believe that YPEL3 has the potential
to be a novel predictor of distant metastasis as well as a
promising therapeutic target in NPC.
NPC has a high rate of local invasion and early metasta-
sis [20–22]; intensity-modulated radiotherapy has greatly
improved the local control of NPC, but distant metastasis
contributes to the majority of treatment failure and death
in patients with NPC [23, 24]. Therefore, it is vital to de-
tect metastasis-associated biomarkers that can effectively
Fig. 3 Effects of YPEL3 silencing on NPC cell migration and invasion in vitro. a Representative western blotting analysis of YPEL3 silencing in CNE-2 and
SUNE-1 cells. GAPDH served as the loading control. b-d Representative images and quantification of the effects of YPEL3 silencing on the migratory and
invasive abilities of CNE-2 and SUNE-1 cells as determined by wound healing (b), Transwell migration (c), and invasion assays (d). All of the experiments
were performed at least three times. Data presented are the mean ± SD; **P< 0.01 compared with control using Student t-test
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Fig. 4 YPEL3 overexpression inhibited EMT and its correlation with EMT markers. a Immunofluorescence staining and quantification analysis of E-cadherin
and vimentin expression levels (×100). b, c Western blot analysis of EMT marker expression levels in NPC cells in which YPEL3 was overexpressed (b) or
silenced (c). d Correlations between YPEL3 expression and E-cadherin and vimentin expression in NPC tissue samples (n= 10). All of the experiments were
performed at least three times. Data presented are the mean ± SD; **P< 0.01, *P< 0.05 compared with control using Student t-test
Fig. 5 YPEL3 suppressed lung metastasis in vivo. Nude BALB/C mice were intravenously injected via the tail vein with SUNE-1 cells stably overexpression
YPEL3 or vector (n= 9 in each group). a Representative images of macroscopic lung metastases, arrowheads indicate the metastatic nodes; b Quantification
of the average number of macroscopic metastatic nodes formed on the lung surface; c Representative images of HE staining (×100); d Quantification of
the average number of microscopic metastatic nodes formed in the lungs based on pathological analysis of HE-stained sections. Data presented are the
mean ± SD; **P< 0.01 compared with control using Student t-test
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distinguish patients with NPC who are at high risk of
metastasis, and further develop novel treatment strategies
for NPC.
YPEL3, first identified as SUAP, is classified as a tumor
suppressor for two reasons. First, its activation led to
IL3 removal in a myeloid precursor cell line [7]. Second,
its expression is downregulated in many cancers and it
plays critical roles in cancer cell proliferation, motility,
and apoptosis [7, 8]. In the present study, YPEL3 expres-
sion levels were decreased in NPC cell lines and tissue
samples at both mRNA and protein level; furthermore,
YPEL3 overexpression inhibited SUNE-1 and CNE-2 cell
invasion, metastasis, and EMT in vitro and in vivo. These
findings indicate that YPEL3 plays a tumor-suppressive
role in NPC, which is consistent with the role of YPEL3 in
other cancers [6–8].
EMT contributes to cancer cell invasion, metastatic
dissemination, and acquisition of therapeutic resistance
[25]. Multiple signaling pathways, including the nuclear
factor kappa B (NF-kB), Wnt, transforming growth
factor-β (TGF-β), and Notch signaling pathways, are
involved in regulating EMT [26–30]. Wnt/β-catenin
plays a critical role in EMT induction and mainten-
ance [31, 32]. Dysregulated signaling of the Wnt/β-ca-
tenin signaling pathway increases the malignancy of
various human cancers, including NPC [33–37]. In this
study, we observed that YPEL3 increased membrane-
associated β-catenin but decreased nuclear β-catenin. It is
possible that YPEL3 decreases the level of Wnt mediators,
leading to reduced Wnt activity and β-catenin destruction.
Wnt binding to its membrane receptor activates intra-
cellular signaling and leads to the dissociation of β-catenin
from the degradation complex consisting of Axin, APC,
CK1 and GSK3β [38, 39]. β-catenin has been reported to
be aberrantly accumulated in human tumors, while GSK-
3β can induce ubiquitination and proteasomal degradation
of β-catenin [40, 41]. In addition, c-myc expression is
thought to be an indicator of Wnt/β-Catenin activity.
Fig. 6 YPEL3 inhibited the Wnt/β-catenin signaling pathway. a Representative western blotting and quantification analysis of GSK-3β, β-catenin,
c-MYC, and cyclin D1 expression levels after YPEL3 overexpression. b Representative western blotting and quantification analysis of GSK-3β,
β-catenin, c-MYC, and cyclin D1 expression levels after YPEL3 silencing. c YPEL3 inhibited the nuclear (Nu) translocation of β-catenin. Cyto,
cytoplasmic. All of the experiments were performed at least three times. Data presented are the mean ± SD; *P < 0.05 and **P < 0.01 compared with
control using Student t-test
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Therefore, we examined the changes to the downstream
target genes of the Wnt/β-catenin signaling pathway by
western blotting. YPEL3 overexpression improved GSK-
3βexpression levels and suppressed β-catenin, c-MYC,
and cyclin D1 expression, whereas silencing YPEL3 in-
creased their expression. The present study confirms that
YPEL3 is an important tumor suppressor in NPC and has
identified novel YPEL3/Wnt/β-catenin signaling in NPC
metastasis.
Conclusions
In this research, we systematically analyzed YPEL3 func-
tion and mechanism in NPC. Given the importance of
YPEL3 expression and the Wnt/β-catenin signaling
pathway in NPC development and progression, our find-
ings not only provide further understanding of the mo-
lecular mechanisms underlying NPC metastasis, but also
identify aberrant Wnt/β-catenin signaling as a promising
new therapeutic target for NPC. Further research to val-
idate this hypothesis is underway.
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